FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3083697690> ?p ?o ?g. }

• W3083697690 abstract "Introduction: Stage III colon cancer patients undergo surgery followed by adjuvant chemotherapy (ACT) according to clinical guidelines. However, 50% would be cured by surgery alone and are being overtreated, while 30-35% will relapse despite adjuvant treatment. This means that only 15-20% of the patients benefit from ACT. Therefore, there is a need for better prognostic biomarkers to stratify patients for ACT. Detection of cell-free circulating tumor DNA (ctDNA) in blood after surgery is indicative of minimal residual disease and highly prognostic for disease recurrence. Hence, detecting liquid biopsy ctDNA is a promising approach to guide treatment decisions in stage III colon cancer. Aim: Determine prognostic value of ctDNA in stage III colon cancer patients treated with ACT in order to reduce futile treatment. Methods: 315 stage III colon cancer patients treated with ACT will be included in the prospective observational study “PROVENC3” (PROgnostic Value of Early Notification by Ctdna in Colon Cancer stage 3). The Prospective Dutch Colorectal Cancer Cohort (PLCRC) infrastructure organizes accrual of colorectal cancer patients in more than 50 hospitals in the Netherlands, among which 25 hospitals that accrue patients for PROVENC3. If informed consent is provided, blood is collected at baseline, post-surgery, post-ACT and every six months up to 3 years, and shipped to a central location. Tumor-informed detection of mutations in ctDNA will be performed by combined analysis of targeted sequencing of a panel of >30 genes in cfDNA (PGDx elio plasma test) and a panel of >500 genes in DNA from formalin-fixed paraffin-embedded tumor tissue (PGDx elio tissue complete assay). The clinical, pathological, and molecular data will be handled according to the FAIR (findable, accessible, interoperable and reusable) principles and integrated in cBioPortal. Results and future directions: Around 125 patients and 400 blood samples included to date. Once sequencing data are obtained we will determine: 1) the proportion of ctDNA-positive and ctDNA-negative patients after surgery and the corresponding recurrence rates; 2) the prognostic value of ctDNA pre-surgery; and 3) the lead time between ctDNA detection and recurrence. Ultimately, the results of this study will be used to model and design an ethically acceptable and cost-effective ctDNA-guided interventional trial, to reduce futile ACT and its associated side-effects in stage III colon cancer patients. Citation Format: Carmen Rubio Alarcon, Dave E. van der Kruijssen, Lana Meiqari, Linda J. Bosch, John K. Simmons, Victor E. Velculescu, Daan van den Broek, Cornelis J. Punt, Veerle M. Coupe, Miriam Koopman, Gerrit A. Meijer, Geraldine R. Vink, Remond J. Fijneman. Liquid biopsy cell-free circulating tumor DNA as prognostic biomarker for stage III colon cancer patients [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 3096." @default.
• W3083697690 created "2020-09-11" @default.
• W3083697690 creator A5006560755 @default.
• W3083697690 creator A5009039158 @default.
• W3083697690 creator A5038985386 @default.
• W3083697690 creator A5042679671 @default.
• W3083697690 creator A5043942519 @default.
• W3083697690 creator A5049451329 @default.
• W3083697690 creator A5053630554 @default.
• W3083697690 creator A5061172196 @default.
• W3083697690 creator A5070586913 @default.
• W3083697690 creator A5077029853 @default.
• W3083697690 creator A5078470750 @default.
• W3083697690 creator A5081322280 @default.
• W3083697690 creator A5087219811 @default.
• W3083697690 date "2020-08-13" @default.
• W3083697690 modified "2023-10-16" @default.
• W3083697690 title "Abstract 3096: Liquid biopsy cell-free circulating tumor DNA as prognostic biomarker for stage III colon cancer patients" @default.
• W3083697690 doi "https://doi.org/10.1158/1538-7445.am2020-3096" @default.
• W3083697690 hasPublicationYear "2020" @default.
• W3083697690 type Work @default.
• W3083697690 sameAs 3083697690 @default.
• W3083697690 citedByCount "0" @default.
• W3083697690 crossrefType "proceedings-article" @default.
• W3083697690 hasAuthorship W3083697690A5006560755 @default.
• W3083697690 hasAuthorship W3083697690A5009039158 @default.
• W3083697690 hasAuthorship W3083697690A5038985386 @default.
• W3083697690 hasAuthorship W3083697690A5042679671 @default.
• W3083697690 hasAuthorship W3083697690A5043942519 @default.
• W3083697690 hasAuthorship W3083697690A5049451329 @default.
• W3083697690 hasAuthorship W3083697690A5053630554 @default.
• W3083697690 hasAuthorship W3083697690A5061172196 @default.
• W3083697690 hasAuthorship W3083697690A5070586913 @default.
• W3083697690 hasAuthorship W3083697690A5077029853 @default.
• W3083697690 hasAuthorship W3083697690A5078470750 @default.
• W3083697690 hasAuthorship W3083697690A5081322280 @default.
• W3083697690 hasAuthorship W3083697690A5087219811 @default.
• W3083697690 hasConcept C121608353 @default.
• W3083697690 hasConcept C126322002 @default.
• W3083697690 hasConcept C142724271 @default.
• W3083697690 hasConcept C143998085 @default.
• W3083697690 hasConcept C146357865 @default.
• W3083697690 hasConcept C151730666 @default.
• W3083697690 hasConcept C152110520 @default.
• W3083697690 hasConcept C172680121 @default.
• W3083697690 hasConcept C2775934546 @default.
• W3083697690 hasConcept C2778258057 @default.
• W3083697690 hasConcept C2779234561 @default.
• W3083697690 hasConcept C2779529041 @default.
• W3083697690 hasConcept C2781197716 @default.
• W3083697690 hasConcept C526805850 @default.
• W3083697690 hasConcept C54355233 @default.
• W3083697690 hasConcept C55493867 @default.
• W3083697690 hasConcept C71924100 @default.
• W3083697690 hasConcept C86803240 @default.
• W3083697690 hasConceptScore W3083697690C121608353 @default.
• W3083697690 hasConceptScore W3083697690C126322002 @default.
• W3083697690 hasConceptScore W3083697690C142724271 @default.
• W3083697690 hasConceptScore W3083697690C143998085 @default.
• W3083697690 hasConceptScore W3083697690C146357865 @default.
• W3083697690 hasConceptScore W3083697690C151730666 @default.
• W3083697690 hasConceptScore W3083697690C152110520 @default.
• W3083697690 hasConceptScore W3083697690C172680121 @default.
• W3083697690 hasConceptScore W3083697690C2775934546 @default.
• W3083697690 hasConceptScore W3083697690C2778258057 @default.
• W3083697690 hasConceptScore W3083697690C2779234561 @default.
• W3083697690 hasConceptScore W3083697690C2779529041 @default.
• W3083697690 hasConceptScore W3083697690C2781197716 @default.
• W3083697690 hasConceptScore W3083697690C526805850 @default.
• W3083697690 hasConceptScore W3083697690C54355233 @default.
• W3083697690 hasConceptScore W3083697690C55493867 @default.
• W3083697690 hasConceptScore W3083697690C71924100 @default.
• W3083697690 hasConceptScore W3083697690C86803240 @default.
• W3083697690 hasLocation W30836976901 @default.
• W3083697690 hasOpenAccess W3083697690 @default.
• W3083697690 hasPrimaryLocation W30836976901 @default.
• W3083697690 hasRelatedWork W1993861922 @default.
• W3083697690 hasRelatedWork W2341114501 @default.
• W3083697690 hasRelatedWork W2746620571 @default.
• W3083697690 hasRelatedWork W2768827395 @default.
• W3083697690 hasRelatedWork W2902255362 @default.
• W3083697690 hasRelatedWork W2944104549 @default.
• W3083697690 hasRelatedWork W2965812107 @default.
• W3083697690 hasRelatedWork W2983668961 @default.
• W3083697690 hasRelatedWork W4304091561 @default.
• W3083697690 hasRelatedWork W2617018585 @default.
• W3083697690 isParatext "false" @default.
• W3083697690 isRetracted "false" @default.
• W3083697690 magId "3083697690" @default.
• W3083697690 workType "article" @default.